Abstract
The concept of "pharmacogenetics" addresses genetically determined variation in how individuals respond to drugs. Accordingly, specific genetic variants have been suggested as contributors to a reduced response to various antiplatelet drugs. Aspirin is a cornerstone in secondary cardiovascular prevention and has been thoroughly investigated. The efficacy of aspirin is well documented, although with considerable interindividual variation. According to meta-analyses, a reduced antiplatelet effect of aspirin confers an increased risk of cardiovascular events. The platelet response to aspirin is assessed by in vitro evaluation of thromboxane-dependent platelet function. A reduced antiplatelet effect of aspirin can be explained by several mechanisms, which are largely determined by clinical, pharmacodynamic, biological and genetic factors. During the past decade, numerous studies have identified genetic polymorphisms significantly associated with cardiovascular events and modulating the antiplatelet effect of aspirin. However, results have been contradictory allowing only few firm conclusions to be drawn. Polymorphisms in genes encoding glycoproteins (IIb/IIIa, Ia/IIa, VI and Ib), cyclooxygenases (1 and 2), adenosine diphosphate receptors (P2Y1 and P2Y12) and proteins of importance for haemostasis (thromboxane A2 receptor, coagulation factor XIII, etc.) have been investigated. In particular, a polymorphism in the gene encoding glycoprotein IIb/IIIa has been associated with a reduced antiplatelet effect of aspirin.
The additive value of an individual’s genetic makeup in predicting the antiplatelet effect of aspirin and the risk of cardiovascular events remains controversial. The present review outlines the pharmacology of aspirin and provides an overview of specific genetic variations considered to influence the antiplatelet effect of aspirin.Keywords: Aspirin, genetic testing, pharmacogenetics, platelet glycoprotein IIb-IIIa complex, platelet aggregation inhibitors, platelet function tests, polymorphisms
Current Pharmaceutical Design
Title:Pharmacogenetics of the Antiplatelet Effect of Aspirin
Volume: 18 Issue: 33
Author(s): Morten Wurtz, Steen Dalby Kristensen, Anne-Mette Hvas and Erik Lerkevang Grove
Affiliation:
Keywords: Aspirin, genetic testing, pharmacogenetics, platelet glycoprotein IIb-IIIa complex, platelet aggregation inhibitors, platelet function tests, polymorphisms
Abstract: The concept of "pharmacogenetics" addresses genetically determined variation in how individuals respond to drugs. Accordingly, specific genetic variants have been suggested as contributors to a reduced response to various antiplatelet drugs. Aspirin is a cornerstone in secondary cardiovascular prevention and has been thoroughly investigated. The efficacy of aspirin is well documented, although with considerable interindividual variation. According to meta-analyses, a reduced antiplatelet effect of aspirin confers an increased risk of cardiovascular events. The platelet response to aspirin is assessed by in vitro evaluation of thromboxane-dependent platelet function. A reduced antiplatelet effect of aspirin can be explained by several mechanisms, which are largely determined by clinical, pharmacodynamic, biological and genetic factors. During the past decade, numerous studies have identified genetic polymorphisms significantly associated with cardiovascular events and modulating the antiplatelet effect of aspirin. However, results have been contradictory allowing only few firm conclusions to be drawn. Polymorphisms in genes encoding glycoproteins (IIb/IIIa, Ia/IIa, VI and Ib), cyclooxygenases (1 and 2), adenosine diphosphate receptors (P2Y1 and P2Y12) and proteins of importance for haemostasis (thromboxane A2 receptor, coagulation factor XIII, etc.) have been investigated. In particular, a polymorphism in the gene encoding glycoprotein IIb/IIIa has been associated with a reduced antiplatelet effect of aspirin.
The additive value of an individual’s genetic makeup in predicting the antiplatelet effect of aspirin and the risk of cardiovascular events remains controversial. The present review outlines the pharmacology of aspirin and provides an overview of specific genetic variations considered to influence the antiplatelet effect of aspirin.Export Options
About this article
Cite this article as:
Wurtz Morten, Dalby Kristensen Steen, Hvas Anne-Mette and Lerkevang Grove Erik, Pharmacogenetics of the Antiplatelet Effect of Aspirin, Current Pharmaceutical Design 2012; 18 (33) . https://dx.doi.org/10.2174/138161212803251907
DOI https://dx.doi.org/10.2174/138161212803251907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Puerarin Stimulates Osteogenic Differentiation and Bone Formation Through the ERK1/2 and p38-MAPK Signaling Pathways
Current Molecular Medicine Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Current HIV Treatment Guidelines - An Overview
Current Pharmaceutical Design Green Synthesis of Zinc Oxide Nanoparticles (ZnO NPs) using Aqueous Extract of <i>Tagetes Erecta</i> flower and Evaluation of its Antioxidant, Antimicrobial, and Cytotoxic activities on HeLa cell line.
Current Biotechnology Reperfusion Therapies in Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Meet Our Editorial Board Member
Current Cardiology Reviews Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth
Anti-Cancer Agents in Medicinal Chemistry Extraction of Triacylglycerols and Fatty Acids Using Supercritical Fluids - Review
Current Analytical Chemistry A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Pindolol Augmentation of Antidepressant Response
Current Drug Targets Apoptosis in COPD
Current Respiratory Medicine Reviews